Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28499187 | 0.82 | FFAR1 (0.47) | FFAR1GRM5CES2CES1 | |
| SCHEMBL28500241 | 0.81 | CES2 (0.45) | FFAR1CES2CES1 | |
| SCHEMBL401353 | 0.80 | NPSR1 (0.50) | VCPFFAR1MAPTFFAR4CES1 | |
| SCHEMBL28506510 | 0.79 | FFAR1 (0.49) | VCPFFAR1GRM5FFAR4 | |
| SCHEMBL29961750 | 0.79 | FFAR1 (0.49) | VCPFFAR1GRM5FFAR4 | |
| SCHEMBL20089259 | 0.77 | VCP (0.55) | VCPFFAR1ACACBCA2CA12 | |
| SCHEMBL29062301 | 0.77 | VCP (0.40) | VCPFFAR1ACACBCA2CA12 | |
| SCHEMBL670335 | 0.75 | VCP (0.58) | VCPFFAR1ACACBCA2CA12 | |
| SCHEMBL12430908 | 0.75 | VCP (0.53) | VCPFFAR1ACACBCA2CA12 | |
| SCHEMBL14126185 | 0.74 | VCP (0.52) | VCPFFAR1ACACBCA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112174877-B | Preparation method of 2, 4-diaryl-6-trifluoromethylpyridine derivative | 华侨大学 | 2022-07-29 | — | — | CN | claimed |
| CN-112174877-A | Preparation method of 2, 4-diaryl-6-trifluoromethylpyridine derivative | 华侨大学 | 2021-01-05 | — | — | CN | claimed |
| CN-117658910-A | 3-amido quinoline structure-containing compound and synthesis method thereof | 河南大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-112174877-B | Preparation method of 2, 4-diaryl-6-trifluoromethylpyridine derivative | 华侨大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-112174877-A | Preparation method of 2, 4-diaryl-6-trifluoromethylpyridine derivative | 华侨大学 | 2021-01-05 | — | — | CN | disclosed |
| US-20050209459-A1 | Processes for the preparation of 1,5-diryl-3-substituted-pyrazoles | REDDY M V R | 2005-09-22 | — | — | US | disclosed |
| EP-1562947-A1 | 4-AMINO-5-PHENYL-7-CYCLOHEXYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-6906196-B2 | Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles | ONCONOVA THERAPEUTICS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1436285-A4 | PROCESSES FOR THE PREPARATION OF 1,5-DIARYL-3-SUBSTITUTED-PYRAZOLES | ONCONOVA THERAPEUTICS INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1436285-A2 | PROCESSES FOR THE PREPARATION OF 1,5-DIARYL-3-SUBSTITUTED-PYRAZOLES | Onconova Therapeutics, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004043962-A1 | 4-AMINO-5-PHENYL-7-CYCLOHEXYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2004-05-27 | — | — | WO | disclosed |
| US-6706927-B2 | INTERMEDIATES IN PREPARATION OF 1,5-DIARYLPYRAZOLE ANTIINFLAMMATORY AGENTS | ONCONOVA THERAPEUTICS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030199707-A1 | ALKYNE KETONES | ONCONOVA THERAPEUTICS, INC. | 2003-10-23 | — | — | US | disclosed |
| US-6579988-B2 | Condensation cyclization of an alkyne and a para-sulfone or sulfonamide phenyl hydrazine | ONCONOVA THERAPEUTICS, INC. | 2003-06-17 | — | — | US | disclosed |
| US-20030109709-A1 | Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles | ONCONOVA THERAPEUTICS, INC. | 2003-06-12 | — | — | US | disclosed |
| US-20030096853-A1 | PROCESSES FOR THE PREPARATION OF 1,5-DIARYLPYRAZOLES | ONCONOVA THERAPEUTICS, INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2003024958-A2 | PROCESSES FOR THE PREPARATION OF 1,5-DIARYL-3-SUBSTITUTED-PYRAZOLES | ONCONOVA THERAPEUTICS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024400-A2 | PROCESS FOR THE PREPARATION OF 1,5-DIARYLPYRAZOLES | ONCONOVA THERAPEUTICS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209459-A1 | Processes for the preparation of 1,5-diryl-3-substituted-pyrazoles | CYP2E1, CYP1A1, CYP1B1 | VCP 3953/4885FFAR1 3367/4885ACACB 2051/4885 |
| US-20030096853-A1 | PROCESSES FOR THE PREPARATION OF 1,5-DIARYLPYRAZOLES | CBR1, CYP1A1, CYP1B1 | VCP 4702/4885FFAR1 1640/4885ACACB 3436/4885 |
| US-20030199707-A1 | ALKYNE KETONES | CBR1, CBR3, CYC1 | VCP 4794/4885FFAR1 254/4885ACACB 717/4885 |
| US-20030109709-A1 | Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles | CYP1B1, CYP1A1, CYP2E1 | VCP 4369/4885FFAR1 2544/4885ACACB 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.